Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 30;77(12):1503-1516.
doi: 10.1016/j.jacc.2021.01.050.

Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis

Paaladinesh Thavendiranathan  1 , Lili Zhang  2 , Amna Zafar  3 , Zsofia D Drobni  4 , Syed S Mahmood  5 , Marcella Cabral  6 , Magid Awadalla  7 , Anju Nohria  8 , Daniel A Zlotoff  7 , Franck Thuny  9 , Lucie M Heinzerling  10 , Ana Barac  11 , Ryan J Sullivan  12 , Carol L Chen  13 , Dipti Gupta  13 , Michael C Kirchberger  14 , Sarah E Hartmann  3 , Jonathan W Weinsaft  15 , Hannah K Gilman  3 , Muhammad A Rizvi  16 , Bojan Kovacina  6 , Caroline Michel  6 , Gagan Sahni  17 , Ana González-Mansilla  18 , Antonio Calles  18 , Francisco Fernández-Avilés  18 , Michael Mahmoudi  19 , Kerry L Reynolds  12 , Sarju Ganatra  20 , Juan José Gavira  21 , Nahikari Salterain González  21 , Manuel García de Yébenes Castro  21 , Raymond Y Kwong  22 , Michael Jerosch-Herold  22 , Otavio R Coelho-Filho  23 , Jonathan Afilalo  6 , Eduardo Zataraín-Nicolás  18 , A John Baksi  24 , Bernd J Wintersperger  25 , Oscar Calvillo-Arguelles  26 , Stephane Ederhy  27 , Eric H Yang  28 , Alexander R Lyon  29 , Michael G Fradley  30 , Tomas G Neilan  31
Affiliations

Myocardial T1 and T2 Mapping by Magnetic Resonance in Patients With Immune Checkpoint Inhibitor-Associated Myocarditis

Paaladinesh Thavendiranathan et al. J Am Coll Cardiol. .

Abstract

Background: Myocarditis is a potentially fatal complication of immune checkpoint inhibitor (ICI) therapy. Data on the utility of cardiovascular magnetic resonance (CMR) T1 and T2 mapping in ICI myocarditis are limited.

Objectives: This study sought to assess the value of CMR T1 and T2 mapping in patients with ICI myocarditis.

Methods: In this retrospective study from an international registry of patients with ICI myocarditis, clinical and CMR findings (including T1 and T2 maps) were collected. Abnormal T1 and T2 were defined as 2 SD above site (vendor/field strength specific) reference values and a z-score was calculated for each patient. Major adverse cardiovascular events (MACE) were a composite of cardiovascular death, cardiogenic shock, cardiac arrest, and complete heart block.

Results: Of 136 patients with ICI myocarditis with a CMR, 86 (63%) had T1 maps and 79 (58%) also had T2 maps. Among the 86 patients (66.3 ± 13.1 years of age), 36 (41.9%) had a left ventricular ejection fraction <55%. Across all patients, mean z-scores for T1 and T2 values were 2.9 ± 1.9 (p < 0.001) and 2.2 ± 2.1 (p < 0.001), respectively. On Siemens 1.5-T scanner (n = 67), native T1 (1,079.0 ± 55.5 ms vs. 1,000.3 ± 22.1 ms; p < 0.001) and T2 (56.2 ± 4.9 ms vs. 49.8 ± 2.2 ms; p < 0.001) values were elevated compared with reference values. Abnormal T1 and T2 values were seen in 78% and 43% of the patients, respectively. Applying the modified Lake Louise Criteria, 95% met the nonischemic myocardial injury criteria and 53% met the myocardial edema criteria. Native T1 values had excellent discriminatory value for subsequent MACE, with an area under the curve of 0.91 (95% confidence interval: 0.84 to 0.98). Native T1 values (for every 1-unit increase in z-score, hazard ratio: 1.44; 95% confidence interval: 1.12 to 1.84; p = 0.004) but not T2 values were independently associated with subsequent MACE.

Conclusions: The use of T1 mapping and application of the modified Lake Louise Criteria provides important diagnostic value, and T1 mapping provides prognostic value in patients with ICI myocarditis.

Keywords: Lake Louise Criteria; T1 mapping; T2 mapping; cardiovascular magnetic resonance; immune checkpoint inhibitor; major adverse cardiovascular event; myocarditis.

PubMed Disclaimer

Conflict of interest statement

Funding Support and Author Disclosures Dr. Thavendiranathan was supported, in part, through the Canadian Institutes of Health Research New Investigator Award (FRN 147814) and a Canada Research Chair in Cardio-Oncology. This work is supported by the New York Academy of Medicine's Glorney-Raisbeck Award to Dr. Mahmood. Dr. Sullivan was supported, in part, through the National Institutes of Health (NIH)/National Cancer Institute (RO1CA229851, UH2CA207355, RO1CA193970). Dr. C.L. Chen, and Dr. D. Gupta were supported, in part, through the NIH/National Cancer Institute P30CA008748. Dr. Neilan was supported, in part, through the Kohlberg Foundation, the NIH/National Heart, Lung, and Blood Institute (RO1HL130539, RO1HL137562, and K24HL150238), and the NIH/Harvard Center for AIDS Research (P30 AI060354). Dr. Thavendiranathan has received Speakers Bureau fees from Amgen, Takeda, and BI. Dr. Mahmood has received consulting fees from OMR Globus, Alpha Detail, and Opinion Research Team. Dr. Nohria has received research grant support from Amgen; and has served a consultant for Takeda Oncology. Dr. Heinzerling has received consulting, advisory board, and speaker fees from MSD, BMS, Roche, Novartis, Amgen, and Curevac. Dr. Sullivan has served as a consultant for Merck and Novartis. Dr. Groarke has received research support from Amgen. Dr. Neilan has received advisory fees from Parexel, BMS, H3 Biomedicine, AbbVie, and Intrinsic Imaging. Dr. Neilan has received grant support from AstraZeneca. Dr. Wintersperger has received research support and speaker honoraria from Siemens Healthineers (the University Health Network has a master research agreement with Siemens Healthineers); and is an inventor of the IG fitting method owned by the University Health Network (US10314548B2). Dr. Yang has received research funding from CSL Behring. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.

Figures

Figure 1:
Figure 1:. Multi-contrast and parametric CMR imaging in patient with confirmed ICI myocarditis (1.5T).
(a) Representative short axis T2-weighted SPAIR without focal signal abnormality; (b) Mid-ventricular short axis MOLLI T1-map demonstrates diffusely elevated T1 values (local normal reference: 1006±24ms) while (c) same slice T2-map demonstrate normal global T2 values (local normal reference: 52±3ms); (d) Post-contrast LGE imaging demonstrates faint mid-myocardial enhancement (arrow) in the mid-ventricular anteroseptum; (e) 3-chamber cine bSSFP image demonstrates a pericardial effusion (*); (f-h) coronary CT angiography performed for exclusion of possible coronary artery disease demonstrated calcified and non-calcified changes (predominately in LAD; f) without significant coronary artery stenosis.
Figure 2.
Figure 2.. Kaplan–Meier curves of MACE free survival in patients with normal and abnormal T1 values (left panel) and T2 values (right panel).
Abnormal values were defined as above mean+2SD of the site, CMR vendor/field strength specific reference ranges.
Figure 3.
Figure 3.. Receiver-Operating-Characteristic (ROC) curves for major adverse cardiovascular events for cardiovascular magnetic resonance T1 and T2 mapping.
T1/T2 values were converted to z-scores for combined analysis.
Central Illustration:
Central Illustration:. A proposed approach to CMR assessment of ICI myocarditis with incorporation of parametric mapping techniques.
Arrowheads delineate band-like subepicardial late gadolinium enhancement (LGE), block arrows highlight elevated signal intensity on T2 weighted image, and (*) demonstrates the presence of pericardial effusion on a cine bSSFP image.
See this image and copyright information in PMC

Comment in

References

    1. Lyon AR, Yousaf N, Battisti NML, Moslehi J, Larkin J. Immune checkpoint inhibitors and cardiovascular toxicity. The lancet oncology 2018;19:e447–e458. - PubMed
    1. Zhang L, Awadalla M, Mahmood SS et al.Cardiovascular magnetic resonance in immune checkpoint inhibitor-associated myocarditis. European heart journal 2020. - PMC - PubMed
    1. Wang DY, Salem JE, Cohen JV et al.Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis. JAMA oncology 2018;4:1721–1728. - PMC - PubMed
    1. Bonaca MP, Olenchock BA, Salem JE et al.Myocarditis in the Setting of Cancer Therapeutics: Proposed Case Definitions for Emerging Clinical Syndromes in Cardio-Oncology. Circulation 2019;140:80–91. - PMC - PubMed
    1. Biesbroek PS, Hirsch A, Zweerink A et al.Additional diagnostic value of CMR to the European Society of Cardiology (ESC) position statement criteria in a large clinical population of patients with suspected myocarditis. European heart journal cardiovascular Imaging 2018;19:1397–1407. - PubMed

Publication types

Substances